Abstract  Description  Claims  Drawing  Search report  Cited references 

Z Mol Ther   [0021]  [0021] 
The Metabolic Syndrome and Cardiovascular Risk   [0048] 
Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death   [0048] 
Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis   [0048] 
The metabolic syndrome - A new worldwide definition   [0048] 
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus   [0048] 
Executive Summary of The Third Report of The National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)   [0048] 
Prevalence of the Metabolic Syndrome Defined by the International Diabetes Federation Among Adults in the U.S.   [0048] 
Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study   [0048] 
Mechanisms linking obesity with cardiovascular disease   [0048] 
Fatty Acids, Obesity, and Insulin Resistance: Time for a Reevaluation   [0048] 
Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study   [0048] 
PLASMA TRIGLYCERIDE LEVEL AND MORTALITY FROM CORONARY ARTERY DISEASE   [0048] 
Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association   [0048] 
National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Chol   [0048] 
Cardiac hypertrophy and diastolic function in physically well trained and in obese men   [0048] 
I. BioGPS and MyGene.info: organizing online, gene-centric information   [0048] 
Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone   [0048] 
Cellular actions of the insulin-like growth factor binding proteins   [0048] 
Insulin-like growth factor binding protein (IGFBP)4 accounts for the connective tissue distribution of endothelial cell IGFBPs perfused through the isolated heart   [0048] 
IGFBP-2 at the interface of growth and metabolism--implications for childhood obesity   [0048] 
Circulating Levels of Free Insulin-like Growth Factors in Obese Subjects: the Impact of Type 2 Diabetes   [0048] 
Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome   [0048] 
IGF-binding protein-2 protects against the development of obesity and insulin resistance   [0048] 
Antidiabetic effects of IGFBP2, a leptin-regulated gene   [0048] 
Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo   [0048] 
Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model   [0048] 
Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure   [0048] 
Long-term Correction of Very Long-chain Acyl-CoA Dehydrogenase Deficiency in Mice Using AAV9 Gene Therapy   [0048] 
Echocardiographic Assessment of Left Ventricular Mass and Systolic Function in Mice   [0048] 
Apolipoprotein O is mitochondrial and promotes lipotoxicity in heart   [0048] 
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms   [0048] 
The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients   [0048] 
Left-ventricular hypertrophy and obesity: a systematic review and meta-analysis of echocardiographic studies   [0048] 
Cardiac Remodeling in Obesity   [0048] 
The link between the metabolic syndrome and cancer   [0048] 
Insulin-like growth factor-I induces hypertrophy with increased expression of muscle specific genes in cultured rat cardiomyocytes   [0048] 
Eppenberger-Eberhardt M, Froesch ER, Eppenberger HM. Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes   [0048] 
Differential Cardiac Effects of Growth Hormone and Insulin-like Growth Factorl in the Rat   [0048] 
BEYOND CARRIER PROTEINS Comparative endocrinology of the insulin-like growth factor-binding protein   [0048] 
Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure   [0048] 
An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice   [0048] 
AAV-mediated in vivo functional selection of tissue-protective factors against ischaemia   [0048] 
Gene therapy clinical trials worlwide to 2012- an update   [0048] 
Design of a Phase 2b Trial of Intracoronary Administration of AAV1/SERCA2a in Patients With Advanced Heart Failure   [0048] 
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy   [0048] 
Adeno-associated virus finds its disease   [0048]